OrganisationDE
Evonik
German specialty chemicals company operating energy-intensive European production sites.
Last refreshed: 22 May 2026 · Appears in 1 active topic
Key Question
How does Germany's gas-set electricity price affect Evonik's specialty chemical margins?
Timeline for Evonik
#1118 May
Operated at 62-68% capacity utilisation
European Energy Markets: Chemicals 62-68% as the new running floorCommon Questions
- Who owns Evonik and what does it produce?
- Evonik is majority-owned (approximately 59%) by RAG-Stiftung, Germany's former coal mining legacy foundation, and produces specialty chemicals including methionine, hydrogen peroxide, and silica.Source: Evonik official
- How does Germany's high electricity price affect Evonik's production costs?
- At EUR 62-68/MWh, Germany's CCGT-set power floor raises costs for Evonik's continuous-process chemical plants, compressing specialty margins against Asian and Middle Eastern producers operating at lower energy prices.Source: european-energy-markets briefing
- What is RAG-Stiftung and why does it own Evonik?
- RAG-Stiftung is a German foundation created to manage the long-term liabilities of the former Ruhr coal mining industry. It holds approximately 59% of Evonik to generate stable cash flows that fund mine remediation and pension obligations.Source: RAG-Stiftung official
Background
Evonik is among the energy-intensive German chemical producers cited in the EUR 62-68/MWh power cost floor analysis. Its continuous-process specialty chemical production at German sites faces margin pressure as gas-set CCGT generation sustains high wholesale power costs through 2026.
How the World Sees Them
RAG-Stiftung (owner)
The foundation's need for stable long-run cash flows from Evonik constrains the company's ability to simply exit German production; elevated energy costs must be managed or absorbed.
German industry broadly
Evonik is part of the coalition of German energy-intensive producers making the political case for power cost relief, citing the EUR 62-68/MWh floor as incompatible with long-term European manufacturing.
Global specialty chemical buyers
Evonik's clients in nutrition and healthcare depend on European-manufactured amino acids and additives; production relocation would disrupt supply chains with limited short-run alternatives.